公开(公告)号：US11414459B2

公开(公告)日：2022-08-16

申请号：US16650943

申请日：2018-09-27

申请人： Kinoxis Therapeutics Pty Ltd

发明人： Michael Kassiou ,  Damien Gulliver ,  Tristan Reekie ,  Timothy Katte ,  William Jorgensen ,  Eryn Werry

IPC分类号： A61K38/00 ,  C07K7/16 ,  A61P25/18 ,  A61P25/30 ,  A61P25/22

摘要： The present disclosure relates to compounds of Formula I being cyclic metabolites of oxytocin. These derivatives have enhanced selectivity for the oxytocin receptor.

公开(公告)号：US11491165B2

公开(公告)日：2022-11-08

申请号：US16439570

申请日：2019-06-12

申请人： Kinoxis Therapeutics Pty Ltd

发明人： Michael Kassiou ,  William Jorgensen ,  Eryn Werry ,  Tristan Reekie ,  Michael Bowen ,  Iain McGregor

IPC分类号： A61K31/5517 ,  A61P25/00

摘要： Disclosed herein are compounds according to Formula I; a pharmaceutical composition including, consisting essentially of, or consisting of: a pharmaceutically acceptable compound of Formula I and a pharmaceutically acceptable carrier, diluent, or excipient; the use of compounds of Formula I in the preparation of a medicament; and a method including administering a pharmaceutical compositions comprising the compound of Formula I to a patient. The compounds, compositions, use, and methods are directed to the treatment of neurological, psychiatric disorders which are characterised by a fundamental disruption of social behaviour, and substance use disorders.